Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kai Zhang has a total of 86 co-authors. Here are the top co-authors by number of shared publications:

  • Ya-Wen Wang

    Department of Breast Surgery, General Surgery, Qilu Hospital of Shandong University

    10 shared publications
  • Can Liu

    Department of Thyroid and Breast Surgery, Jinan Third People's Hospital

    8 shared publications
  • Yan-Duo Chen

    Department of Pediatric Surgery, Central Hospital Affiliated to Shandong First Medical University

    8 shared publications
  • Xu Chen

    Department of Pathology, Qilu Hospital of Shandong University, Jinan, Shandong, China

    6 shared publications
  • Yuan Lin

    Department of Breast Surgery, General Surgery, Qilu Hospital of Shandong University, Jinan, People’s Republic of China

    6 shared publications
  • Yan-Yan Wang

    Center of Health Management, Qilu Hospital of Shandong University, Jinan, People’s Republic of China

    5 shared publications

Latest Publications

  • Open Access

    Circular RNAs in tumor immunity and immunotherapy of breast cancer

    by Yu Jiang, Ya-Wen Wang, Kai Zhang

    As the stable and conserved circular non-coding RNAs, circular RNAs (circRNAs) have assumed growing significance in regulating breast cancer immunity and immunotherapy. This review focuses on elucidating the molecular mechanisms through which circRNAs influence the efficacy of breast cancer immunotherapy. Specifically, circRNAs modulate the levels and stability of critical immune checkpoints, including PD-L1 and various cytokines. They achieve this by acting as competing endogenous RNAs (ceRNAs) to sequester miRNAs, functioning as protein scaffolds, and thereby modulating gene expression and tumor immune evasion. Furthermore, circRNAs are capable of facilitating communication between tumor cells and immune cells. In addition, it can be translated into proteins that aid in remodeling the tumor immune microenvironment. These changes may include driving the polarization of immunosuppressive M2-type macrophages, while suppressing the infiltration and functional activity of cytotoxic T cells and natural killer cells. These findings highlight the significant promise of circRNAs serving as novel biomarkers and candidate therapeutic targets. Targeting specific circRNAs is anticipated to emerge as an effective approach for enhancing the efficacy of current immune checkpoint inhibitors, potentially helping to overcome drug resistance encountered in immunotherapy. Furthermore, it offers potential for the development of novel circRNA-based vaccines. Collectively, these advancements pave the way for improving the prognosis of breast cancer immunotherapy and open new avenues for future research and clinical translation.

  • Open Access

    Identification of endogenous reference genes for RT-qPCR analysis in breast cancer and matched adjacent tissues

    by Yue Meng, Ya-Wen Wang, Zhi-Bao Xu, Zhong-Qi Qiao, Can Liu, Yan-Duo Chen, Yao Xu, Kai Zhang

    Background: Real-time quantitative PCR (RT-qPCR), essential for gene expression and biomarker studies, requires stable endogenous reference genes (RGs) for normalization. This study aimed to identify consistently expressed RGs in breast cancer and adjacent tissues to facilitate comparative analyses of breast cancer-related gene expression. Material and methods: Five candidate RGs (β-actin, 18S rRNA, PUM1, RPLP0, TFRC) were analyzed by RT-qPCR from 30 breast cancer patients. Threshold cycle (Ct) values were evaluated using descriptive statistics, and stability of RGs was assessed using RefFinder, integrating GeNorm, NormFinder, ΔCt, and BestKeeper algorithms. Results: In cancer tissues, descriptive statistics showed that 18S rRNA was a suitable RG (Ct Range = 3.96; Mean Ct=8.43; SD = 0.84). RefFinder identified TFRC as the most stable RG (GM = 1.19), followed by 18S rRNA (GM = 1.41). In adjacent tissues, TFRC was find with its narrowest Ct range (Ct range = 6.29) and highest stability (GM = 1.00) by RefFinder. However, GeNorm and BestKeeper indicated instability for TFRC (M = 2.364, SD = 4.30), exceeding the stability threshold values of 1.5 and 1, respectively. Adjacent tissues displayed significantly higher Ct values than cancer tissues. TFRC may serve as the suitable RG for detecting gene expression when concerning both breast cancer and adjacent tissues (GM = 1.19), though, GeNorm and BestKeeper indicated its instability (M = 2.364, SD = 4.30). Conclusion: TFRC and 18S rRNA may be suitable RGs in breast cancer tissues, while all five candidates were not stable in adjacent tissues. Larger studies are needed to confirm these findings.

  • miRNAs Associated with Axillary Lymph Node Metastasis in Breast Cancer: A Systematic Review and Meta-Analysis

    by Yuan Lin, Yan-Yan Wang, Zhi-Bao Xu, Lei Dong, Can Liu, Xu Chen, Kai Zhang

    Some microRNAs (miRNAs) may have potential as biomarkers for axillary lymph node metastasis (ALNM) in breast cancer. PubMed was systematically searched from its inception to October 2023 using the search term 'miRNA and breast cancer lymph node metastasis' to identify miRNAs reported in three or more relevant publications. Each qualifying miRNA was then paired with 'breast cancer' as search terms across four databases (PubMed, Embase, Web of Science, and Cochrane Library) covering the same time span. Studies investigating miRNA associations with ALNM in breast cancer were included and the evaluation indicators (odds ratio [OR]) or standardized mean difference [SMD]) were calculated. Nine miRNAs were frequently reported to be associated with breast cancer ALNM: miR-206, miR-21, miR-155, miR-124, miR-10b, miR-30a, miR-200c, miR-4521, and miR-101. Patients with high expression of miR-155 (OR 3.41 [1.92-6.06]) or low expression of miR-200c (OR 0.36 [0.17-0.77]) were more likely to experience ALNM. Compared with patients without lymph node metastasis, patients with positive ALNM had elevated expression levels of miR-21 (SMD 1.39 [0.66-2.13]), miR-155 (SMD 0.91 [0.17-1.65]), and miR-10b (SMD 0.63 [0.02-1.23]), and decreased expression levels of miR-200c (SMD - 0.44 [- 0.84 to - 0.05]) and miR-124 (SMD - 2.29 [- 3.93 to - 0.65]). High expression of miRNA-155, miRNA-21, and miRNA-10b, and low expression of miRNA-200c and miRNA-124, were significantly correlated with ALNM in breast cancer patients. miRNAs are expected to become biomarkers for predicting ALNM in breast cancer patients, although more clinical trials are needed for validation.


  • ASO Author Reflections: MicroRNAs as Predictive Biomarkers for Axillary Lymph Node Metastasis in Breast Cancer

    by Yuan Lin, Yan-Yan Wang, Zhi-Bao Xu, Lei Dong, Can Liu, Ya-Wen Wang, Xu Chen, Kai Zhang

  • Open Access

    Coding circular RNA in human cancer

    by Yuan Lin, Yawen Wang, Lixin Li, Kai Zhang

    Circular RNA (circRNA) is a covalently closed single-stranded RNA that lacks 5' and 3' ends and has long been considered a noncoding RNA. With the development of high-throughput sequencing and bioinformatics technology, the understanding of circRNA has become increasingly advanced. Recent studies have shown that some cytoplasmic circRNAs can be effectively translated into detectable proteins, further indicating the importance of circRNA in cellular pathology and physiological functions. Internal ribosome entry site (IRES) and N6-methyladenosine (m6A) mediated cap-independent translation initiation are considered potential mechanisms of circRNA translation. Multiple circRNAs have been shown to play crucial roles in human cancer. This paper provides an overview of the nature and functions of circRNA and describes the possible mechanisms underlying the initiation of circRNA translation. We summarized the emerging functions of circRNA-encoded proteins in human cancer. Finally, we discuss the therapeutic potential of circRNAs and the challenges of research in this field. This review on circRNA translation will reveal a hidden human proteome and enhance our understanding of the importance of circRNAs in human malignant tumors.


  • Open Access

    Circular RNAs as Biomarkers in Breast Cancer Diagnosis, Prognosis, Molecular Types, Metastasis and Drug Resistance

    by Li-Xin Li, Yun Hao, Lei Dong, Zhong-Qi Qiao, Shun-Chao Yang, Yan-Duo Chen, Kai Zhang, Ya-Wen Wang

    Breast cancer is one of the leading causes of cancer-related deaths in women worldwide. Circular RNAs (circRNAs), a novel class of endogenous noncoding RNA with a covalently closed continuous loop that lacks the 5′-cap structure and the 3′-poly A tail, are more stable than linear RNAs and less susceptible to degradation by nucleases. CircRNAs are widespread in multiple mammalian genomes and have been detected in various tissues, cells and body fluids. Increasing evidence shows that abnormal expression of circRNAs is involved in the development of a variety of diseases, including breast cancer. Numerous studies have explored the potential of circRNAs as biomarkers in various malignant tumors. In this review, we aim to provide a comprehensive overview of the latest advances in circRNAs as promising biomarkers in the early diagnosis, prognosis, molecular type, metastasis and drug resistance of breast cancer.


  • Open Access

    A case report of breast Rosai-Dorfman disease and a literature review

    by Yuan Lin, Ya-Wen Wang, Li-Xin Li, Zhong-Qi Qiao, Xu Chen, Yan-Duo Chen, Can Liu, Kai Zhang

    Rosai-Dorfman disease (RDD) is a rare idiopathic histiocytoproliferative disease that usually affects the lymph nodes of the head and neck, but can also involve extranodal sites such as the skin, sinuses, and soft tissues. Breast RDD is exceedingly rare. It may be clinically and radiographically similar to neoplastic and non-neoplastic diseases. We report a case of breast RDD in a 68-year-old female patient and describe the clinical imaging and pathological features of the patient. The management of extranodal RDD is individualized, and there are no standardized guidelines for treatment. We highlight the importance of considering the diagnosis of extranodal breast RDD, and suggest that surgical resection is an effective way to treat this disease, particularly for single-focal breast lesions with RDD.


  • Open Access

    Breast tuberculosis with bone destruction mimicking breast cancer with bone metastasis: a case report and literature review

    by Li-Xin Li, Ya-Wen Wang, Yuan Lin, Yan-Duo Chen, Xu Chen, Xin Li, Xiao-Lin Zhou, Liang Su, Mei-Ying Lin, Kai Zhang

    Background: Tuberculosis (TB) poses a significant global health challenge. While the incidence of breast TB (BTB) is relatively low, it can easily be mistaken for breast cancer or breast granulomatous lobulitis, potentially delaying timely intervention. The gold standard for diagnosis consists of Mycobacterium TB culture and Ziehl-Neelsen staining. Treatment typically consists of a combination of anti-TB therapy and surgical intervention. Case Description: Our research group recently reported a case of BTB accompanied by rib bone destruction. Initially, imaging examinations suggested breast cancer with bone metastasis. However, subsequent real-time ultrasound-guided biopsy revealed chronic inflammation with granulomatous inflammation and extensive necrosis, which led to the diagnosis of BTB. Further T cells spot test (T-SPOT) testing predicted the likelihood of the presence of TB infection, and magnetic resonance imaging (MRI) indicated a high likelihood of TB. A biopsy of the breast lesions was performed and subsequent polymerase chain reaction (PCR) analysis of the aspirated specimens confirmed the presence of DNA from the Mycobacterium TB complex, as well as genes associated with rifampicin resistance. These findings led to the definitive diagnosis of BTB complicated by bone destruction. The patient underwent a 4-month course of anti-TB medication, followed by surgical intervention and an additional regimen of anti-TB drugs. Nine months post-surgery, the patient exhibited no indications of recurrence. Conclusions: The diagnosis of BTB with bone destruction is challenging, and clinicians need to be vigilant not to misdiagnose it as breast cancer or granulomatous lobulitis.


  • Open Access

    Polyamine Anabolism Promotes Chemotherapy‐Induced Breast Cancer Stem Cell Enrichment

    by Guangyu Ji, Jia Liu, Zhiqun Zhao, Jie Lan, You Yang, Zheng Wang, Huijing Feng, Kai Ji, Xiaofeng Jiang, Huize Xia, et al.

    Breast cancer patients may initially benefit from cytotoxic chemotherapy but experience treatment resistance and relapse. Chemoresistant breast cancer stem cells (BCSCs) play a pivotal role in cancer recurrence and metastasis, however, identification and eradication of BCSC population in patients are challenging. Here, an mRNA‐based BCSC signature is developed using machine learning strategy to evaluate cancer stemness in primary breast cancer patient samples. Using the BCSC signature, a critical role of polyamine anabolism in the regulation of chemotherapy‐induced BCSC enrichment, is elucidated. Mechanistically, two key polyamine anabolic enzymes, ODC1 and SRM, are directly activated by transcription factor HIF‐1 in response to chemotherapy. Genetic inhibition of HIF‐1‐controlled polyamine anabolism blocks chemotherapy‐induced BCSC enrichment in vitro and in xenograft mice. A novel specific HIF‐1 inhibitor britannin is identified through a natural compound library screening, and demonstrate that coadministration of britannin efficiently inhibits chemotherapy‐induced HIF‐1 transcriptional activity, ODC1 and SRM expression, polyamine levels, and BCSC enrichment in vitro and in xenograft and autochthonous mouse models. The findings demonstrate the key role of polyamine anabolism in BCSC regulation and provide a new strategy for breast cancer treatment.